Final analysis of the phase III FeDeriCa trial in HER2-positive early breast cancer: subcutaneous fixed-dose pertuzumab–trastuzumab vs IV pertuzumab plus trastuzumab showed comparable 4-year invasive disease-free survival (88.5% vs 89.6%), with no new safety signals.
RCT
Jackisch et al. Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer